Man Group PLC Regeneron Pharmaceuticals, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 60,521 shares of REGN stock, worth $43.9 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

60,521

Previous 51,744 16.96%

Holding current value

$43.9 Million

Previous $54.4 Million 16.99%

% of portfolio

0.18%

Previous 0.14%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $8.99 Million - $10.5 Million	8,777 Added 16.96%	60,521 $63.6 Million
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $50.1 Million - $60.8 Million	-56,728 Reduced 52.3%	51,744 $54.4 Million
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $13.5 Million - $14.8 Million	14,912 Added 15.94%	108,472 $104 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $41.2 Million - $46.9 Million	53,173 Added 131.66%	93,560 $82.2 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $52.8 Million - $64.4 Million	-76,249 Reduced 65.37%	40,387 $33.2 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $60.6 Million - $71.8 Million	86,518 Added 287.26%	116,636 $83.8 Million
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $32 Million - $38.9 Million	-47,002 Reduced 60.95%	30,118 $24.7 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $40.6 Million - $44 Million	57,473 Added 292.53%	77,120 $55.6 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $10.8 Million - $13.7 Million	-18,903 Reduced 49.04%	19,647 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $4.7 Million - $6.34 Million	8,580 Added 28.63%	38,550 $22.8 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $69.8 Million - $81.9 Million	-117,219 Reduced 79.64%	29,970 $20.9 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $36.3 Million - $44.8 Million	66,819 Added 83.14%	147,189 $93 Million
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $16.4 Million - $19.5 Million	-28,583 Reduced 26.23%	80,370 $48.6 Million
Q2 2021 Aug 16, 2021	SELL	$472.8 - $558.54 $5.35 Million - $6.32 Million	-11,314 Reduced 9.41%	108,953 $60.9 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $33.5 Million - $41.1 Million	74,920 Added 165.21%	120,267 $56.9 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $8.15 Million - $10.4 Million	17,041 Added 60.2%	45,347 $21.9 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $3.08 Million - $3.72 Million	-5,658 Reduced 16.66%	28,306 $15.8 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $1.62 Million - $2.11 Million	3,280 Added 10.69%	33,964 $21.2 Million
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $794,393 - $1.17 Million	2,363 Added 8.34%	30,684 $15 Million
Q4 2019 Feb 18, 2020	BUY	$274.13 - $376.51 $3.75 Million - $5.16 Million	13,695 Added 93.63%	28,321 $10.6 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $651,655 - $758,723	-2,383 Reduced 14.01%	14,626 $4.06 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $3.89 Million - $5.38 Million	12,980 Added 322.16%	17,009 $5.33 Million
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $612,815 - $723,971	-1,647 Reduced 29.02%	4,029 $1.65 Million
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $164,551 - $197,489	-490 Reduced 7.95%	5,676 $2.12 Million
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $25,984 - $30,229	-74 Reduced 1.19%	6,166 $2.49 Million
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $11,668 - $14,144	-41 Reduced 0.65%	6,240 $2.15 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $1.98 Million - $2.47 Million	6,281 New	6,281 $2.16 Million

Others Institutions Holding REGN

# of Institutions

1,535

Shares Held

83.8M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $77.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account